BACKGROUND: The prevalence of pressure ulcers of the foot is a major health care problem in frail elderly patients. A pressure sore dramatically increases the cost of medical and nursing care, and effective treatment has always been an essential nursing concern. Management options for pressure ulcers include local wound care; surgical repair; and, more recently, topical application of growth factors. OBJECTIVE: To examine the effects of topical treatment with nerve growth factor in patients with severe, noninfected pressure ulcers of the foot. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Teaching nursing home of Catholic University of the Sacred Heart, Italy. PATIENTS: 36 persons with pressure ulcers of the foot. INTERVENTION: 18 patients received nerve growth factor treatment, and 18 patients received only conventional topical treatment. MEASUREMENTS: The course of the ulcers during follow-up was evaluated by tracing the perimeter of the wound onto sterile, transparent block paper and determining the stage. RESULTS: At baseline, the treatment and control groups did not differ across demographic variables, clinical characteristics, and functional measures. The mean area (+/-SD) of the ulcers was 1012 +/- 633 mm2 in the treatment group and 1012 +/- 655 mm2 in the control group (P > 0.2). The average reduction in pressure ulcer area at 6 weeks was statistically significantly greater in the treatment group than in the control group (738 +/- 393 mm2 vs. 485 +/- 384 mm2; P = 0.034). CONCLUSION: Topical application of nerve growth factor may be an effective therapy for patients with severe pressure ulcers.

Topical treatment of pressure ulcers with nerve growth factor - A randomized clinical trial.

Aloe L;
2003

Abstract

BACKGROUND: The prevalence of pressure ulcers of the foot is a major health care problem in frail elderly patients. A pressure sore dramatically increases the cost of medical and nursing care, and effective treatment has always been an essential nursing concern. Management options for pressure ulcers include local wound care; surgical repair; and, more recently, topical application of growth factors. OBJECTIVE: To examine the effects of topical treatment with nerve growth factor in patients with severe, noninfected pressure ulcers of the foot. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Teaching nursing home of Catholic University of the Sacred Heart, Italy. PATIENTS: 36 persons with pressure ulcers of the foot. INTERVENTION: 18 patients received nerve growth factor treatment, and 18 patients received only conventional topical treatment. MEASUREMENTS: The course of the ulcers during follow-up was evaluated by tracing the perimeter of the wound onto sterile, transparent block paper and determining the stage. RESULTS: At baseline, the treatment and control groups did not differ across demographic variables, clinical characteristics, and functional measures. The mean area (+/-SD) of the ulcers was 1012 +/- 633 mm2 in the treatment group and 1012 +/- 655 mm2 in the control group (P > 0.2). The average reduction in pressure ulcer area at 6 weeks was statistically significantly greater in the treatment group than in the control group (738 +/- 393 mm2 vs. 485 +/- 384 mm2; P = 0.034). CONCLUSION: Topical application of nerve growth factor may be an effective therapy for patients with severe pressure ulcers.
2003
NEUROBIOLOGIA E MEDICINA MOLECOLARE
139/8
635
641
NGF
Ulcere cutanee
decubito
malattie autoimmuni
La molecola NGF è una neurotrofina scoperta circa 50 anni fa che è ampiamente studiata in centri di ricerca italiani ed esteri per valutarne il potenziale terapeutico in patologie a carico del sistema nervoso centrale e periferico ed in ulcere della cute come dimostrato negli ultimi anni dalle ricerche condotte nel nostro laboratorio. Partendo da questi dati pre-clinici, alcune industrie farmaceutiche hanno iniziato a produrre la molecola con metodi di ingegneria genetica. IMPACT FACTOR 2002 = 11,13 Comment in: Ann Intern Med. 2003 Oct 21;139(8):694-5. Ann Intern Med. 2003 Oct 21;139(8):I10.
8
info:eu-repo/semantics/article
262
Landi, F; Aloe, L; Russo, A; Cesari, M; Onder, G; Bonini, S; Carbonin, Pu; Bernabei, R
01 Contributo su Rivista::01.01 Articolo in rivista
none
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/166788
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact